Cibc World Markets Corp Takes Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Cibc World Markets Corp purchased a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 1,285,300 shares of the company’s stock, valued at approximately $41,014,000. Cibc World Markets Corp owned approximately 1.03% of Apellis Pharmaceuticals as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of APLS. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Apellis Pharmaceuticals in the 4th quarter worth $430,000. EverSource Wealth Advisors LLC raised its stake in shares of Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after acquiring an additional 758 shares in the last quarter. AlphaQuest LLC raised its stake in shares of Apellis Pharmaceuticals by 8,083.8% during the 4th quarter. AlphaQuest LLC now owns 17,186 shares of the company’s stock worth $548,000 after acquiring an additional 16,976 shares in the last quarter. Amundi increased its position in Apellis Pharmaceuticals by 10,967.2% during the 4th quarter. Amundi now owns 329,582 shares of the company’s stock valued at $10,876,000 after buying an additional 326,604 shares in the last quarter. Finally, Edgestream Partners L.P. increased its position in Apellis Pharmaceuticals by 10.5% during the 4th quarter. Edgestream Partners L.P. now owns 109,883 shares of the company’s stock valued at $3,506,000 after buying an additional 10,482 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on APLS shares. Royal Bank of Canada cut their price objective on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a report on Monday, March 3rd. JPMorgan Chase & Co. increased their price objective on Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Wedbush cut their price target on shares of Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Finally, The Goldman Sachs Group cut their price target on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a report on Monday, March 3rd. Eight analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Apellis Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $45.53.

Apellis Pharmaceuticals Stock Up 1.2 %

Shares of APLS opened at $24.66 on Monday. The firm has a market cap of $3.10 billion, a P/E ratio of -12.15 and a beta of 0.92. Apellis Pharmaceuticals, Inc. has a 12 month low of $23.77 and a 12 month high of $59.91. The stock’s 50 day moving average is $28.33 and its two-hundred day moving average is $30.50. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $212.50 million for the quarter, compared to analysts’ expectations of $197.92 million. During the same quarter last year, the company earned ($0.73) EPS. The firm’s revenue for the quarter was up 45.2% compared to the same quarter last year. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Caroline Baumal sold 2,816 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total value of $95,208.96. Following the sale, the insider now directly owns 55,560 shares of the company’s stock, valued at $1,878,483.60. The trade was a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $179,288.90. Following the completion of the sale, the chief executive officer now directly owns 307,415 shares in the company, valued at $8,822,810.50. This represents a 1.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 65,934 shares of company stock worth $1,950,261 over the last 90 days. 6.80% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).